{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:19:01Z","timestamp":1793305141747,"version":"4.5.0"},"reference-count":106,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1097\/mpa.0b013e3181ec1380","type":"journal-article","created":{"date-parts":[[2010,7,21]],"date-time":"2010-07-21T07:10:36Z","timestamp":1279696236000},"page":"784-798","source":"Crossref","is-referenced-by-count":152,"title":["NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors"],"prefix":"10.1097","volume":"39","author":[{"given":"Alexandria T.","family":"Phan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kjell","family":"\u00d6berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn H.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Strosberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric P.","family":"Krenning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Kocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene A.","family":"Woltering","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Maples","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-8-20210212","first-page":"425","article-title":"Karzinoide tumoren des dunndarms.","volume":"1","author":"Oberndorfer","year":"1907","journal-title":"Frankf Z Pathol"},{"issue":"18","key":"R2-8-20210212","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"5","key":"R3-8-20210212","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrc1610","article-title":"Molecular genetics of multiple endocrine neoplasia types 1 and 2.","volume":"5","author":"Marx","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"R4-8-20210212","first-page":"322","article-title":"Carcinoid tumours. Frequency in a defined population during a 12-year period.","volume":"84","author":"Berge","year":"1976","journal-title":"Acta Pathol Microbiol Scand A"},{"issue":"2","key":"R5-8-20210212","first-page":"560","article-title":"Carcinoid tumors. An analysis of 2,837 cases.","volume":"36","year":"1975","journal-title":"Cancer"},{"issue":"3","key":"R6-8-20210212","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ijc.1473","article-title":"Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden.","volume":"94","author":"Hemminki","year":"2001","journal-title":"Int J Cancer"},{"issue":"4","key":"R7-8-20210212","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors.","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"R9-8-20210212","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/(SICI)1096-9098(199610)63:2<99::AID-JSO6>3.0.CO;2-J","article-title":"Carcinoid tumors of the lung: immuno- and ligandohistochemistry, analysis of integrated optical density, syntactic structure analysis, clinical data, and prognosis of patients treated surgically.","volume":"63","author":"Kayser","year":"1996","journal-title":"J Surg Oncol"},{"issue":"5","key":"R10-8-20210212","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2214\/ajr.170.5.9574618","article-title":"Evaluation of primary pulmonary carcinoid tumors using FDG PET.","volume":"170","author":"Erasmus","year":"1998","journal-title":"AJR Am J Roentgenol"},{"issue":"10","key":"R11-8-20210212","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1053\/hupa.2000.19294","article-title":"Pulmonary atypical carcinoid: predictors of survival in 106 cases.","volume":"31","author":"Beasley","year":"2000","journal-title":"Hum Pathol"},{"issue":"6","key":"R13-8-20210212","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2265.2003.01931.x","article-title":"Octreoscan in patients with bronchial carcinoid tumours.","volume":"59","author":"Granberg","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"R14-8-20210212","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/00005382-199104000-00011","article-title":"Bronchial carcinoid tumors: radiologic observations in 49 cases.","volume":"6","author":"Nessi","year":"1991","journal-title":"J Thorac Imaging"},{"issue":"2","key":"R15-8-20210212","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1148\/radiographics.22.2.g02mr01351","article-title":"Bronchial carcinoid tumors of the thorax: spectrum of radiologic findings.","volume":"22","author":"Jeung","year":"2002","journal-title":"Radiographics"},{"issue":"6","key":"R16-8-20210212","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1378\/chest.119.6.1647","article-title":"Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature.","volume":"119","author":"Fink","year":"2001","journal-title":"Chest"},{"issue":"5","key":"R17-8-20210212","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1010-7940(02)00089-1","article-title":"Surgery in bronchial carcinoids: experience with 83 patients.","volume":"21","author":"Kurul","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3","key":"R18-8-20210212","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1055\/s-2005-837539","article-title":"Carcinoid tumors of the lung and multimodal therapy.","volume":"53","author":"Divisi","year":"2005","journal-title":"Thorac Cardiovasc Surg"},{"issue":"2","key":"R19-8-20210212","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/(SICI)1522-2586(200002)11:2<141::AID-JMRI10>3.0.CO;2-U","article-title":"Neuroendocrine tumors of the pancreas: spectrum of appearances on MRI.","volume":"11","author":"Semelka","year":"2000","journal-title":"J Magn Reson Imaging"},{"issue":"2","key":"R20-8-20210212","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.mric.2005.03.012","article-title":"MR imaging of the pancreas.","volume":"13","author":"Pamuklar","year":"2005","journal-title":"Magn Reson Imaging Clin N Am"},{"issue":"6","key":"R21-8-20210212","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s003300050221","article-title":"MRI of pancreatic tumors.","volume":"7","author":"Kelekis","year":"1997","journal-title":"Eur Radiol"},{"issue":"887","key":"R22-8-20210212","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1259\/bjr.74.887.741065","article-title":"Imaging appearances of metastases from neuroendocrine tumours of the pancreas.","volume":"74","author":"Debray","year":"2001","journal-title":"Br J Radiol"},{"issue":"1","key":"R23-8-20210212","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2214\/ajr.180.1.1800121","article-title":"MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques.","volume":"180","author":"Dromain","year":"2003","journal-title":"AJR Am J Roentgenol"},{"issue":"11","key":"R24-8-20210212","first-page":"712","article-title":"Experience with somatostatin receptor scintigraphy in the management of pulmonary carcinoid tumors.","volume":"7","author":"Yellin","year":"2005","journal-title":"Isr Med Assoc J"},{"key":"R25-8-20210212","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1994.tb17300.x","article-title":"Radiotherapy with a radiolabeled somatostatin analogue, 111In-DTPA-D-Phe1-octreotide. A case history.","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann N Y Acad Sci"},{"issue":"7","key":"R26-8-20210212","first-page":"1134","article-title":"Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.","volume":"42","author":"Balon","year":"2001","journal-title":"J Nucl Med"},{"issue":"6","key":"R27-8-20210212","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1210\/jc.2004-1938","article-title":"Whole-body (11)C-5-hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and computed tomography.","volume":"90","author":"Orlefors","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"R28-8-20210212","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/JTO.0b013e31818b06e3","article-title":"The IASLC Lung Cancer Staging Project: proposals for the inclusion of broncho-pulmonary carcinoid tumors in the forthcoming (seventh) edition of the TNM Classification for Lung Cancer.","volume":"3","author":"Travis","year":"2008","journal-title":"J Thorac Oncol"},{"issue":"11","key":"R29-8-20210212","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1002\/1097-0142(19811201)48:11<2485::AID-CNCR2820481123>3.0.CO;2-R","article-title":"Follow-up study of thymomas with special reference to their clinical stages.","volume":"48","author":"Masaoka","year":"1981","journal-title":"Cancer"},{"issue":"2","key":"R30-8-20210212","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/00313029800169056","article-title":"Thymic carcinoma: spectrum of differentiation and histologic types.","volume":"30","author":"Suster","year":"1998","journal-title":"Pathology"},{"issue":"5","key":"R32-8-20210212","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/(SICI)1097-0142(19990901)86:5<858::AID-CNCR23>3.0.CO;2-8","article-title":"Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors.","volume":"86","author":"Bajetta","year":"1999","journal-title":"Cancer"},{"issue":"7","key":"R33-8-20210212","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/(SICI)1097-0142(19990401)85:7<1470::AID-CNCR7>3.0.CO;2-S","article-title":"Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas.","volume":"85","author":"Goebel","year":"1999","journal-title":"Cancer"},{"issue":"5","key":"R34-8-20210212","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1054\/bjoc.2000.1659","article-title":"A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours.","volume":"84","author":"Bernini","year":"2001","journal-title":"Br J Cancer"},{"issue":"5","key":"R35-8-20210212","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1365-2265.2004.02030.x","article-title":"Interest of chromogranin A for diagnosis and follow-up of endocrine tumours.","volume":"60","author":"Nehar","year":"2004","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"839","key":"R36-8-20210212","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1136\/pgmj.71.839.542","article-title":"The clinical and laboratory correlates of an increased urinary 5-hydroxyindoleacetic acid.","volume":"71","author":"Tormey","year":"1995","journal-title":"Postgrad Med J"},{"issue":"4","key":"R37-8-20210212","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/ajcn\/42.4.639","article-title":"Serotonin content of foods: effect on urinary excretion of 5-hydroxyindoleacetic acid.","volume":"42","author":"Feldman","year":"1985","journal-title":"Am J Clin Nutr"},{"issue":"4","key":"R38-8-20210212","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1378\/chest.97.4.920","article-title":"Nd:YAG laser photoresection of low-grade malignant tumors of the tracheobronchial tree.","volume":"97","author":"Diaz-Jimenez","year":"1990","journal-title":"Chest"},{"issue":"2","key":"R39-8-20210212","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jtcvs.2007.03.020","article-title":"Sleeve and wedge parenchyma-sparing bronchial resections in low-grade neoplasms of the bronchial airway.","volume":"134","author":"Lucchi","year":"2007","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"R40-8-20210212","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0169-5002(02)00080-6","article-title":"Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark.","volume":"37","author":"Skuladottir","year":"2002","journal-title":"Lung Cancer"},{"issue":"1","key":"R41-8-20210212","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/cncr.23542","article-title":"Bronchopulmonary neuroendocrine tumors.","volume":"113","author":"Gustafsson","year":"2008","journal-title":"Cancer"},{"issue":"2","key":"R42-8-20210212","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S1010-7940(00)00493-0","article-title":"Long-term outcome after resection for bronchial carcinoid tumors.","volume":"18","author":"Ferguson","year":"2000","journal-title":"Eur J Cardiothorac Surg"},{"issue":"4","key":"R43-8-20210212","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1378\/chest.119.4.1143","article-title":"Typical and atypical pulmonary carcinoids: outcome in patients presenting with regional lymph node involvement.","volume":"119","author":"Thomas","year":"2001","journal-title":"Chest"},{"issue":"5","key":"R44-8-20210212","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.athoracsur.2003.10.089","article-title":"Bronchial carcinoid tumors: nodal status and long-term survival after resection.","volume":"77","author":"Cardillo","year":"2004","journal-title":"Ann Thorac Surg"},{"issue":"5","key":"R45-8-20210212","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/S0003-4975(98)00083-6","article-title":"Operative risk and prognostic factors of typical bronchial carcinoid tumors.","volume":"65","author":"Ducrocq","year":"1998","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"R46-8-20210212","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1200\/JCO.2005.04.1202","article-title":"Neuroendocrine neoplasms of the lung: a prognostic spectrum.","volume":"24","author":"Asamura","year":"2006","journal-title":"J Clin Oncol"},{"issue":"4","key":"R47-8-20210212","first-page":"211","article-title":"Bronchopulmonary carcinoids: an analysis of 1,875 reported cases with special reference to a comparison between typical carcinoids and atypical varieties.","volume":"5","author":"Soga","year":"1999","journal-title":"Ann Thorac Cardiovasc Surg"},{"issue":"suppl 2","key":"R48-8-20210212","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/S0169-5002(05)80313-7","article-title":"O-179 Typical and atypical carcinoid tumors (NEC grades 1 and 2): prognostic factors in metastases and local recurrence.","volume":"49","author":"Matilla-Gonzalez","year":"2005","journal-title":"Lung Cancer"},{"issue":"4","key":"R49-8-20210212","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/S0039-6060(97)90090-8","article-title":"Bronchial carcinoid-twenty years' experience defines a selective surgical approach.","volume":"122","author":"Chughtai","year":"1997","journal-title":"Surgery"},{"issue":"1","key":"R51-8-20210212","first-page":"60","article-title":"Bronchial carcinoid tumors: long-term outcome after surgery.","volume":"50","author":"Fiala","year":"2003","journal-title":"Neoplasma"},{"key":"R52-8-20210212","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000423376","article-title":"The role of surgery in N1 and N2 lung cancer.","volume":"28","author":"Martini","year":"1994","journal-title":"Front Radiat Ther Oncol"},{"issue":"1","key":"R53-8-20210212","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0003-4975(98)01063-7","article-title":"Thymic neuroendocrine tumor (thymic carcinoid): a clinicopathologic study in 15 patients.","volume":"67","author":"Fukai","year":"1999","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"R54-8-20210212","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0022-5223(96)70409-9","article-title":"Thymic neuroendocrine carcinoma (carcinoid): a clinicopathologic study of fourteen cases.","volume":"111","author":"de Montpreville","year":"1996","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"5","key":"R56-8-20210212","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1093\/clinchem\/32.5.840","article-title":"Urinary serotonin in the diagnosis of carcinoid tumors.","volume":"32","author":"Feldman","year":"1986","journal-title":"Clin Chem"},{"issue":"3","key":"R57-8-20210212","first-page":"237","article-title":"Carcinoid tumors and syndrome.","volume":"14","author":"Feldman","year":"1987","journal-title":"Semin Oncol"},{"issue":"7","key":"R58-8-20210212","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3109\/00365528809090760","article-title":"Clinical presentation and prognosis of gastrointestinal carcinoid tumours.","volume":"23","author":"Sjoblom","year":"1988","journal-title":"Scand J Gastroenterol"},{"issue":"1","key":"R59-8-20210212","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/172460089801300102","article-title":"Chromogranin A measurement in neuroendocrine tumors.","volume":"13","author":"Ferrari","year":"1998","journal-title":"Int J Biol Markers"},{"issue":"15","key":"R60-8-20210212","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1200\/JCO.2006.10.1535","article-title":"Chromogranin A: is it a useful marker of neuroendocrine tumors?","volume":"25","author":"Campana","year":"2007","journal-title":"J Clin Oncol"},{"issue":"5","key":"R61-8-20210212","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1213\/01.ane.0000284704.57806.0b","article-title":"Intraoperative management of patients with carcinoid heart disease having valvular surgery: a review of one hundred consecutive cases.","volume":"105","author":"Weingarten","year":"2007","journal-title":"Anesth Analg"},{"issue":"4","key":"R62-8-20210212","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF03010865","article-title":"Pre-treatment with somatostatin in the anaesthetic management of a patient with carcinoid syndrome.","volume":"35","author":"Parris","year":"1988","journal-title":"Can J Anaesth"},{"issue":"2","key":"R63-8-20210212","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1213\/00000539-199402000-00032","article-title":"Intraoperative octreotide for refractory carcinoid-induced bronchospasm.","volume":"78","author":"Quinlivan","year":"1994","journal-title":"Anesth Analg"},{"issue":"7","key":"R64-8-20210212","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1007\/BF03017444","article-title":"Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide.","volume":"49","author":"Orbach-Zinger","year":"2002","journal-title":"Can J Anaesth"},{"issue":"7","key":"R65-8-20210212","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/BF02285194","article-title":"Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel.","volume":"40","author":"Harris","year":"1995","journal-title":"Dig Dis Sci"},{"issue":"2","key":"R66-8-20210212","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"issue":"4","key":"R67-8-20210212","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/01.mpa.0000186249.89081.0d","article-title":"Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors.","volume":"31","author":"Woltering","year":"2005","journal-title":"Pancreas"},{"issue":"12","key":"R69-8-20210212","first-page":"1265","article-title":"Phase II trial of rDNA alfa 2b interferon in patients with malignant carcinoid tumor.","volume":"71","author":"Smith","year":"1987","journal-title":"Cancer Treat Rep"},{"issue":"4","key":"R70-8-20210212","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3109\/02841869109092413","article-title":"Treatment of gastrointestinal endocrine tumours with interferon-alpha and octreotide.","volume":"30","author":"Creutzfeldt","year":"1991","journal-title":"Acta Oncol"},{"issue":"5","key":"R71-8-20210212","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3109\/02841869109092426","article-title":"Treatment of metastatic carcinoid tumors and the carcinoid syndrome with recombinant interferon alpha.","volume":"30","author":"Doberauer","year":"1991","journal-title":"Acta Oncol"},{"issue":"5","key":"R72-8-20210212","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/bjc.1992.372","article-title":"Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers.","volume":"66","author":"Biesma","year":"1992","journal-title":"Br J Cancer"},{"issue":"8","key":"R73-8-20210212","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/oxfordjournals.annonc.a058291","article-title":"Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: a randomized trial.","volume":"3","author":"Janson","year":"1992","journal-title":"Ann Oncol"},{"issue":"1","key":"R74-8-20210212","first-page":"35","article-title":"The action of interferon alpha on human carcinoid tumours.","volume":"3","author":"Oberg","year":"1992","journal-title":"Semin Cancer Biol"},{"issue":"10","key":"R75-8-20210212","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1002\/1097-0142(19931115)72:10<3099::AID-CNCR2820721035>3.0.CO;2-4","article-title":"Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group.","volume":"72","author":"Bajetta","year":"1993","journal-title":"Cancer"},{"issue":"2","key":"R76-8-20210212","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/02841869309083918","article-title":"Treatment of carcinoid syndrome with recombinant interferon alpha-2a.","volume":"32","author":"Di Bartolomeo","year":"1993","journal-title":"Acta Oncol"},{"issue":"5","key":"R77-8-20210212","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1097\/00001813-199410000-00001","article-title":"Endocrine tumors of the gastrointestinal tract: systemic treatment.","volume":"5","author":"Oberg","year":"1994","journal-title":"Anticancer Drugs"},{"issue":"2","key":"R78-8-20210212","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1097\/00001813-199603000-00005","article-title":"Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors-an antiangiogenic effect?","volume":"7","author":"Dirix","year":"1996","journal-title":"Anticancer Drugs"},{"issue":"suppl 2","key":"R79-8-20210212","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1093\/annonc\/12.suppl_2.S111","article-title":"Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.","volume":"12","author":"Oberg","year":"2001","journal-title":"Ann Oncol"},{"issue":"4","key":"R80-8-20210212","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bpg.2005.02.012","article-title":"Endocrine tumours of the gastrointestinal tract. Biotherapy for metastatic endocrine tumours.","volume":"19","author":"Shah","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"issue":"1","key":"R81-8-20210212","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000109876","article-title":"Consensus guidelines for the management of patients with digestive neuroendocrine tumours: well-differentiated tumour\/carcinoma of the appendix and goblet cell carcinoma.","volume":"87","author":"Plockinger","year":"2008","journal-title":"Neuroendocrinology"},{"issue":"2","key":"R82-8-20210212","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","article-title":"Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with alpha-interferon.","volume":"32","author":"Janson","year":"1993","journal-title":"Acta Oncol"},{"issue":"5","key":"R83-8-20210212","first-page":"1381","article-title":"Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"issue":"6580","key":"R84-8-20210212","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1136\/bmj.294.6580.1129","article-title":"Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist.","volume":"294","author":"Anderson","year":"1987","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"271","key":"R85-8-20210212","first-page":"1021","article-title":"Therapy for symptoms in the carcinoid syndrome.","volume":"73","author":"Coupe","year":"1989","journal-title":"Q J Med"},{"issue":"8812","key":"R86-8-20210212","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0140-6736(92)93273-P","article-title":"Ondansetron in carcinoid syndrome.","volume":"340","author":"Jacobsen","year":"1992","journal-title":"Lancet"},{"issue":"8806","key":"R87-8-20210212","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/0140-6736(92)91235-Z","article-title":"Ondansetron in carcinoid syndrome.","volume":"339","author":"Platt","year":"1992","journal-title":"Lancet"},{"issue":"15","key":"R88-8-20210212","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJM199310073291503","article-title":"Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea.","volume":"329","author":"von der Ohe","year":"1993","journal-title":"N Engl J Med"},{"issue":"8","key":"R89-8-20210212","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0959-8049(98)00009-4","article-title":"Effects of ondansetron on gastrointestinal symptoms in carcinoid syndrome.","volume":"34","author":"Wymenga","year":"1998","journal-title":"Eur J Cancer"},{"issue":"1","key":"R90-8-20210212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/jcem-29-1-1","article-title":"Cushing's syndrome induced by the ectopic production of ACTH by a bronchial carcinoid.","volume":"29","author":"Jones","year":"1969","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"R91-8-20210212","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0046-8177(84)80151-3","article-title":"Cushing's syndrome produced by a bronchial carcinoid tumor.","volume":"15","author":"DeStephano","year":"1984","journal-title":"Hum Pathol"},{"issue":"3","key":"R92-8-20210212","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7326\/0003-4819-117-3-209","article-title":"The Cushing syndrome induced by bronchial carcinoid tumors.","volume":"117","author":"Limper","year":"1992","journal-title":"Ann Intern Med"},{"issue":"1","key":"R93-8-20210212","first-page":"63","article-title":"Cushing's syndrome induced by bronchopulmonary carcinoid tumours: a review of 98 cases and our experience of two cases.","volume":"56","author":"Scanagatta","year":"2004","journal-title":"Chir Ital"},{"issue":"4","key":"R94-8-20210212","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/0002-9343(84)90284-5","article-title":"Ectopic secretion of a growth hormone-releasing factor. Report of a case of acromegaly with bronchial carcinoid tumor.","volume":"76","author":"Scheithauer","year":"1984","journal-title":"Am J Med"},{"issue":"1","key":"R95-8-20210212","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1445-5994.1987.tb05054.x","article-title":"Resolution of acromegaly after removal of a bronchial carcinoid shown to secrete growth hormone releasing factor.","volume":"17","author":"Carroll","year":"1987","journal-title":"Aust N Z J Med"},{"issue":"2","key":"R96-8-20210212","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/021849230301100229","article-title":"Acromegaly as manifestation of a bronchial carcinoid tumour.","volume":"11","author":"Filosso","year":"2003","journal-title":"Asian Cardiovasc Thorac Ann"},{"issue":"4","key":"R97-8-20210212","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jtcvs.2004.02.033","article-title":"Acromegaly caused by ectopic growth hormone-releasing hormone secretion by a carcinoid bronchial tumor: a rare entity.","volume":"128","author":"Athanassiadi","year":"2004","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"28","key":"R98-8-20210212","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"issue":"7","key":"R99-8-20210212","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/02841860310010547","article-title":"Carcinoid-a comprehensive review.","volume":"42","author":"Schnirer","year":"2003","journal-title":"Acta Oncol"},{"issue":"6","key":"R100-8-20210212","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/bjs.4149","article-title":"Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours.","volume":"90","author":"Kolby","year":"2003","journal-title":"Br J Surg"},{"issue":"14","key":"R101-8-20210212","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","article-title":"Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors-the International Lanreotide and Interferon Alfa Study Group.","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"issue":"10","key":"R102-8-20210212","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","article-title":"Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors.","volume":"13","author":"Ekeblad","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"2","key":"R103-8-20210212","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3390\/curroncol13020006","article-title":"Guidelines for the diagnosis and management of carcinoid tumours. Part 1: The gastrointestinal tract. A statement from a Canadian National Carcinoid Expert Group.","volume":"13","author":"Maroun","year":"2006","journal-title":"Curr Oncol"},{"issue":"6","key":"R104-8-20210212","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00268-001-0015-6","article-title":"Cryoablation, percutaneous alcohol injection, and radiofrequency ablation for treatment of neuroendocrine liver metastases.","volume":"25","author":"Siperstein","year":"2001","journal-title":"World J Surg"},{"issue":"3","key":"R105-8-20210212","first-page":"493","article-title":"Liver metastases of neuroendocrine carcinomas: interventional treatment via transarterial embolization, chemoembolization and thermal ablation.","volume":"66","author":"Vogl","year":"2008","journal-title":"Eur J Radiol"},{"issue":"5","key":"R106-8-20210212","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0002-9610(96)00019-0","article-title":"Synchronous non-small cell lung cancers.","volume":"171","author":"Pommier","year":"1996","journal-title":"Am J Surg"},{"issue":"8","key":"R107-8-20210212","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.21389","article-title":"Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.","volume":"104","author":"Gupta","year":"2005","journal-title":"Cancer"},{"issue":"3","key":"R108-8-20210212","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/COC.0b013e31815e4557","article-title":"Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.","volume":"31","author":"Kennedy","year":"2008","journal-title":"Am J Clin Oncol"},{"issue":"suppl 1","key":"R109-8-20210212","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1016\/j.ijrobp.2007.05.094","article-title":"Quality assurance issues for therapeutic application of radioactive microspheres.","volume":"71","author":"Dezarn","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"R110-8-20210212","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/SLA.0b013e3181728a45","article-title":"90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience.","volume":"247","author":"Rhee","year":"2008","journal-title":"Ann Surg"},{"issue":"3","key":"R111-8-20210212","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1159\/000209849","article-title":"Selective internal radiotherapy with yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study.","volume":"79","author":"Kalinowski","year":"2009","journal-title":"Digestion"},{"issue":"4","key":"R112-8-20210212","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.soc.2008.04.011","article-title":"Development of isolated hepatic perfusion for patients who have unresectable hepatic malignancies.","volume":"17","author":"Jones","year":"2008","journal-title":"Surg Oncol Clin N Am"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006676-201008000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:32:13Z","timestamp":1786041133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006676-201008000-00008"}},"subtitle":["Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus)"],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":106,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0b013e3181ec1380","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}